- Aclaris Therapeutics, Inc.
$107 Million - Follow-OnJoint Bookrunner
- Equillium, Inc.
$65 Million - Initial Public OfferingJoint Bookrunner
- Karyopharm Therapeutics, Inc.
$150 Million - Convertible Senior NotesJoint Bookrunner
- JNJ / Leadership Series: Growth Acceleration with Strong FCF Generation
- CVS / PBMs Are a Big Part of the Solution; Rebate Capture Minimal
- BIIB / Half Full or Half Empty? Alzheimer’s Disease Pulse Call Takeaways